Peer-reviewedLicence not stated
Inebilizumab (Uplizna): Indication: Adults with immunoglobulin G4-related disease: Reimbursement Recommendation
Related
- Inebilizumab (Uplizna): Indication: As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive: Reimbursement Recommendation
- Vamorolone (Agamree): Indication: For the treatment of Duchenne muscular dystrophy in patients 4 years of age and older: Reimbursement Recommendation
- Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation
- Intranasal epinephrine (Neffy): Indication: Emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis in adult and pediatric patients who weigh 30 kg or greater: Reimbursement Recommendation
- Dramatic regression of mass-forming gastric IgG4-related disease with inebilizumab: a case report.
BibTeX
@article{anon2026inebilizumab,
title = {{Inebilizumab (Uplizna): Indication: Adults with immunoglobulin G4-related disease: Reimbursement Recommendation}},
year = {2026},
month = sep,
url = {https://europepmc.org/article/MED/42899953},
}
RIS
TY - JOUR
TI - Inebilizumab (Uplizna): Indication: Adults with immunoglobulin G4-related disease: Reimbursement Recommendation
PY - 2026
DA - 2026/09/01
UR - https://europepmc.org/article/MED/42899953
ER -